News & Events

May 11, 2022

BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30...

May 9, 2022

BrainsWay Appoints Eric Hirt as Vice President of U.S. Sales

Veteran Medical Device Industry Sales and Marketing Executive Has Over 20 Years of Experience BURLINGTON,...

May 4, 2022

BrainsWay to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society

Additional presentations will highlight the utility of Deep TMS™ in Smoking Addiction and OCD BURLINGTON,...

May 2, 2022

BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month

BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work of Mental Health...

April 27, 2022

BrainsWay to Report First Quarter Financial Results on May 11, 2022

BURLINGTON, Mass. and JERUSALEM, April 27, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

March 28, 2022

BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy

Dr. Seidel has more than 20 years of experience in the medical device industry BURLINGTON, Mass. and...

March 15, 2022

BrainsWay to Host Key Opinion Leader Webinar on Deep TMS™ Therapy for Treating Anxious Depression

BURLINGTON, Mass. and JERUSALEM, March 15, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

March 9, 2022

BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights

Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues Continued Progress in Expanding...

March 1, 2022

BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference

BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 28, 2022

BrainsWay to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022

BURLINGTON, Mass. and JERUSALEM, Feb. 28, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 23, 2022

BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression

Results Distinguish Deep TMS as More Effective in Subjects with Higher Anxiety Symptoms, Long Considered...

February 1, 2022

BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

BURLINGTON, Mass. and JERUSALEM, February 1, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

January 31, 2022

BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD

Palmetto GBA Covers Medicare Patients in Seven States BURLINGTON, Mass. and JERUSALEM, January 31, 2022...

January 26, 2022

BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board

World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians...

January 12, 2022

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive...

December 9, 2021

BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects

Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol...

November 30, 2021

BrainsWay to Present at the Sidoti December Micro-Cap Investor Conference

BURLINGTON, Mass. and JERUSALEM, November 30, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

November 17, 2021

BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights

Revenue Growth of 34% Year-over-Year in Q3 2021 Received Regulatory Clearance for Deep TMS™ System...